Atropine was administered orally in a dose ... drugs should be further investigated in the management of very tall children.

OBJECTIVE: To describe the effects of combined trimedoxime (TMB4) and atropine poisoning from automatic injectors (AI) in children. STUDY DESIGN: Data was collected from two sources: calls to the ...

The Singapore Eye Research Institute now has grants to develop artificial intelligence in treating eye diseases. Read more at ...

(Reuters) -Eyenovia will discontinue a late-stage study for its experimental drug-device combination to treat ...

Eyenovia, Inc. EYEN announced the decision to terminate a phase III study evaluating its investigational drug-device product, ...

Eyenovia said it is ending the Phase 3 study of a drug-device combination of low-dose atropine in its Optejet dispensing platform in pediatric progressive myopia and exploring its strategic options ...

CHAPERONE is Eyenovia’s Phase 3 study evaluating its proprietary drug-device combination of low-dose atropine in the Company’s Optejet dispensing platform as a potential treatment for pediatric ...

On Friday, Eyenovia, Inc. (NASDAQ:EYEN) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating ...

Eyenovia said Friday it plans to cut half of its workforce after results from a Phase 3 study missed their primary endpoint. The pharmaceutical company had 57 full-time employees as of March 15. There ...

Eyenovia (EYEN) announced that a review of the CHAPERONE data by an independent Data Review Committee found that the trial is not meeting its ...